About
Haim Pharma Group (HPG) is an Israel-based virtual drug development company, advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company’s lead focus is amyotrophic lateral sclerosis (ALS), with a parallel program in Parkinson’s disease (PD).
HPG is pioneering an oral enteric-coated psilocin capsule Neurosilin designed for stability and controlled release. A U.S. provisional patent filed in 2025 protects the novel approach to treating neurodegenerative diseases.
The therapeutic concept is based on chronic, sub-hallucinogenic dosing, leveraging psilocin’s multimodal mechanisms: serotonin receptor engagement, restoration of glutamatergic balance, neuroplasticity enhancement, mitochondrial protection, and attenuation of neuroinflammation. Together, these actions aim to slow disease progression and stabilize neuronal viability in ALS and PD.
HPG has taken a proactive regulatory path, engaging with the FDA and submitting a briefing package in July 2025, outlining its development strategy and clinical roadmap.
The company operates through a virtual model, coordinating with global CROs, CDMOs, and academic partners. Its work is guided by experienced clinical and development advisors with deep expertise in neurology, biostatistics, and regulatory strategy.
Haim Pharma group is supported by key knowledge leaders in the area of ALS and clinical trials and is committed to redefining the treatment paradigm for ALS leverage psilocin as a personalized, disease-modifying therapy.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Haim Pharma Group's primary focus in drug development?
- Haim Pharma Group (HPG) is focused on advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases, specifically targeting amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
- What is the name of Haim Pharma Group's lead product and its key features?
- Haim Pharma Group's lead product is Neurosilin, an oral enteric-coated psilocin capsule designed for stability and controlled release.
- When did Haim Pharma Group file a U.S. provisional patent for its therapeutic approach?
- Haim Pharma Group filed a U.S. provisional patent in 2025 to protect its novel approach to treating neurodegenerative diseases.
- What is Haim Pharma Group's regulatory engagement strategy with the FDA?
- Haim Pharma Group engaged with the FDA and submitted a briefing package in July 2025, outlining its development strategy and clinical roadmap.
- How does Haim Pharma Group operate its drug development activities?
- Haim Pharma Group operates through a virtual model, coordinating with global Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), and academic partners.
- When was Haim Pharma Group founded?
- Haim Pharma Group was founded in April 2022.
- How many employees does Haim Pharma Group currently have?
- Haim Pharma Group has between 1 and 10 employees.
- What is the total amount of grant funding Haim Pharma Group has received?
- Haim Pharma Group has received a total of $68,000 in grants, including $60,000 from the IIA in September 2025 and $8,000 from the IIA in May 2023.
- What is Haim Pharma Group's current funding stage?
- Haim Pharma Group is currently in the Pre-Funding stage.